Moderna, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Moderna, Inc. (MRNA) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $30.47 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-20.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-02-20
- Moderna, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2021-03-31 was $171.07, a 566.94% increase year-over-year.
- Moderna, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2020-03-31 was $25.65, a 24.58% increase year-over-year.
- Moderna, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2019-03-31 was $20.59.
- Moderna, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $30.47, a 67.73% decline from fiscal 2024.
- Moderna, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $94.42, a 16.46% decline from fiscal 2023.
- Moderna, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $113.03, a 24.67% decline from fiscal 2022.
- Moderna, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $150.05, a 28.35% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2025-12-31 | $30.47 10-K · filed 2026-02-20 | |||
| 2024-12-31 | $94.42 10-K · filed 2025-02-21 | |||
| 2023-12-31 | $113.03 10-K · filed 2024-02-23 | |||
| 2022-12-31 | $150.05 10-K · filed 2023-02-24 | |||
| 2021-12-31 | $209.41 10-K · filed 2022-02-25 | |||
| 2021-09-30 | $195.93 10-Q · filed 2021-11-04 | |||
| 2021-06-30 | $173.82 10-Q · filed 2021-08-05 | |||
| 2021-03-31 | $171.07 10-Q · filed 2021-05-06 | |||
| 2020-12-31 | $36.04 10-K · filed 2021-02-26 | |||
| 2020-09-30 | $33.79 10-Q · filed 2020-10-30 | |||
| 2020-06-30 | $28.66 10-Q · filed 2020-08-06 | |||
| 2020-03-31 | $25.65 10-Q · filed 2020-05-07 | |||
| 2019-12-31 | $19.58 10-K · filed 2020-02-27 | |||
| 2019-09-30 | $20.01 10-Q · filed 2019-11-06 | |||
| 2019-06-30 | $20.24 10-Q · filed 2019-08-08 | |||
| 2019-03-31 | $20.59 10-Q · filed 2019-05-09 | |||
| 2018-12-31 | $17.01 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |